Business Context and Reporting Period
Company: Novartis AG
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 17, 2007
Reporting Period: First half (H1) and Second Quarter (Q2) of 2007
Novartis AG reported strong performance for the first half of 2007, driven by solid contributions across its strategic healthcare portfolio, including Pharmaceuticals, Sandoz (generics), Vaccines and Diagnostics, and Consumer Health. The company is strategically repositioning to focus solely on healthcare, completing the divestment of non-core businesses such as Medical Nutrition and Gerber baby foods.
Key Financial Metrics
| Metric | H1 2007 (USD) | H1 2006 (USD) | % Change (Reported) | % Change (Local Currency) |
|---|---|---|---|---|
| Net Sales | $19.94 billion | $17.48 billion | +14% | +11% |
| Operating Income | $4.67 billion | $4.26 billion | +10% | N/A |
| Operating Margin | 23.4% | 24.4% | -100 bps | N/A |
| Net Income | $4.19 billion | $3.67 billion | +14% | N/A |
| Net Margin | 21.0% | 21.0% | 0 bps | N/A |
| Basic EPS/ADS | $1.78 | $1.56 | +14% | N/A |
Second Quarter 2007 Highlights
- Net Sales: $10.12 billion (+10% reported, +7% local currency).
- Operating Income: $2.22 billion (+8%).
- Net Income: $2.02 billion (+18%).
- Basic EPS/ADS: $0.86 (+18%).
Divisional Performance (H1 2007)
- Pharmaceuticals: Top brands Diovan (+19% lc) and Gleevec/Glivec (+14% lc) drove growth. New brands (Tekturna, Lucentis, Exjade, Exforge) performed dynamically. Growth slowed in Q2 due to Zelnorm suspension and generic competition for Lotrel.
- Sandoz: Net sales expanded 19% to $3.4 billion.
- Vaccines and Diagnostics: Net sales up 45% to $482 million.
- Consumer Health: Net sales up 9% to $2.6 billion.
Material Changes vs. Prior Period
- Revenue Growth: Double-digit growth in reported USD and local currencies, supported by all divisions.
- Profitability: Operating income rose 10% and net income rose 14% year-over-year.
- Headwinds: Q2 Pharmaceuticals growth slowed to 6% due to the suspension of Zelnorm sales (since March) and the onset of generic competition for Lotrel (May) and Lamisil (July).
- Divestitures: Completed sale of Medical Nutrition to Nestlé for $2.5 billion on July 1; Gerber baby foods sale ($5.5 billion) expected to close in H2 2007.
Guidance, Outlook, and Risks
Outlook Revision
- Net Sales: Full-year outlook revised to mid-single-digit growth in local currencies for Group continuing operations. Pharmaceuticals Division outlook revised to low-single-digit growth in local currencies.
- Profitability: Management reaffirms expectations for record operating and net income from continuing operations for the full year 2007.
Capital Allocation
- Share Repurchase: Plans to repurchase up to approximately $4 billion of shares by February 2008. $800 million was already repurchased in H1 2007.
- Funding: Repurchases and targeted acquisitions will be funded by strong free cash flow and proceeds from non-core divestments.
Risks and Contingencies
- Product Risks: Continued negative impact from Zelnorm suspension and generic competition for Lotrel and Lamisil (combined 2006 sales of $2.5 billion).
- Regulatory: Uncertainty regarding clinical trial results, regulatory approvals, and patent protection.
- Market: Pricing pressures and competition in the healthcare sector.
Investor Verification Checklist
- Verify the timeline and final closing of the Gerber baby foods divestment to Nestlé.
- Monitor the impact of generic competition on Lotrel and Lamisil sales in the second half of 2007.
- Track the progress of the $4 billion share repurchase program against the February 2008 deadline.
- Assess the commercial uptake of new regulatory approvals (7 achieved in H1 2007) to offset legacy product declines.
- Review the full quarterly report for detailed segment breakdowns and cash flow statements not fully detailed in this summary.